Skip to content

Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy

Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy - A Randomized Clinical Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01717222
Enrollment
50
Registered
2012-10-30
Start date
2011-12-31
Completion date
2012-10-31
Last updated
2012-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative, Analgesic Requirement, Stress Response, Return of Bowel Activity, Inadequate or Impaired Respiratory Function

Keywords

Lignocaine, Laparoscopic cholecystectomy, Pain relief

Brief summary

Laparoscopic Cholecystectomy is the treatment of choice for patients with symptomatic gall stones. For pain relief following laparoscopic cholecystectomy both intraperitoneal and intravenous administration of lignocaine has been used. But it is not clear from the existing literature which form of administration is more effective for pain relief. Hence this study has been undertaken with the following hypothesis : Intravenous lignocaine is superior to intraperitoneal lignocaine for postoperative pain relief and minimizing the stress response in laparoscopic cholecystectomy.

Detailed description

Laparoscopic Cholecystectomy is the treatment of choice for patients with symptomatic gall stones. For pain relief following laparoscopic cholecystectomy both intraperitoneal and intravenous administration of lignocaine has been used. But it is not clear from the existing literature which form of administration is more effective for pain relief. Hence this study has been undertaken with the following hypothesis : Intravenous lignocaine is superior to intraperitoneal lignocaine for postoperative pain relief and minimizing the stress response in laparoscopic cholecystectomy. In this study the effect of intraperitoneal and intravenous lignocaine will be assessed based on the postoperative pain scores, total analgesic requirement, stress response in the form of total leukocyte count, c-reactive protein levels,return of bowel activity.

Interventions

DRUGIntraperitoneal Lignocaine

Patients will receive 100 ml of 0.2% lignocaine

Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery

Sponsors

Jawaharlal Institute of Postgraduate Medical Education & Research
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patients planned for elective laparoscopic cholecystectomy in the age group of 20 -60 years belonging to American society of anesthesiologists (ASA)score I-II

Exclusion criteria

* Chronic pain diseases other than gall stone disease. * Use of opioids, steroids, Non steroidal anti inflammatory drugs or alcohol. * Allergy and contraindication to Lignocaine. * Conversion to open cholecystectomy. * Patients who do not comprehend Visual analogue scale (VAS) / patient controlled analgesia (PCA).

Design outcomes

Primary

MeasureTime frameDescription
Post operative pain relief1 hour postoperativelyPost operative pain relief will be assessed by visual analogue scale with values between 0 and 10. 0 denotes no pain and 10 denotes worst pain. the patient uses this scale to represent his/her pain at 1 hour postoperatively.

Secondary

MeasureTime frameDescription
Postoperative Analgesic RequirementFirst 24 hours in the postoperative periodPatients will get analgesia through patient controlled analgesia pump (PCA). This pump delivers Morphine for pain relief. This will be delivered at 1 mg/ml bolus dose with a lock out period of 15 minutes without any background infusion of the drug. The total requirement over a period of 24 hours will be noted. Also the time taken for the patient to take the first analgesic dose will be recorded. The total demands and the number of good demands in the PCA pump will also be recorded.
Postoperative pain relief8 hours postoperativelyPost operative pain relief will be assessed by visual analogue scale with values between 0 and 10. 0 denotes no pain and 10 denotes worst pain. the patient uses this scale to represent his/her pain at 8 hours postoperatively

Other

MeasureTime frameDescription
Stress response in the form of Total Leucocyte Count (TLC) and C- reactive protein (CRP)Preoperatively and 48 hours PostoperativelyBlood will be analyzed for TLC and CRP preoperatively and 48 hours postoperatively to assess the stress response
Respiratory FunctionPreoperatively and 48 hours PostoperativelyRespiratory function will be assessed by measuring the peak expiratory flow rate (PEFR)at the above mentioned time frames.
Return of bowel activityupto to 48 hoursThis will be assessed by asking the time at which the patient perceives the first bowel movement and also the time for passage of flatus post surgery.

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026